Johnson Investment Counsel Inc. Increases Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Johnson Investment Counsel Inc. raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,570 shares of the company’s stock after purchasing an additional 160 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Medpace were worth $522,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Pallas Capital Advisors LLC boosted its holdings in Medpace by 179.7% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after purchasing an additional 2,101 shares in the last quarter. Baillie Gifford & Co. boosted its holdings in Medpace by 175.6% in the 3rd quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock valued at $4,966,000 after purchasing an additional 9,478 shares in the last quarter. Barclays PLC lifted its position in shares of Medpace by 71.9% during the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after acquiring an additional 8,275 shares during the period. Oppenheimer Asset Management Inc. lifted its position in shares of Medpace by 6.3% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock valued at $15,179,000 after acquiring an additional 2,675 shares during the period. Finally, Sanctuary Advisors LLC lifted its position in shares of Medpace by 20.5% during the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock valued at $1,738,000 after acquiring an additional 844 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of Medpace stock opened at $324.91 on Thursday. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The company has a market capitalization of $9.90 billion, a P/E ratio of 25.73, a P/E/G ratio of 3.81 and a beta of 1.47. The business has a 50 day moving average price of $340.91 and a 200 day moving average price of $342.00.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Robert W. Baird lifted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.